Diabetes Drug Use During Pregnancy Linked To Child's Weight
Follow all of ScienceDaily's latest research news and top science headlines ! Diabetes drug use during pregnancy linked to child's weight Children born to moms who took metformin face increased risk of obesity When women take the common diabetes medication metformin during pregnancy, it may put their children at increased risk of having obesity or overweight. When women take the common diabetes medication metformin during pregnancy, it may put their children at increased risk of having obesity or overweight. A growing number of pregnant women are taking metformin to treat gestational diabetes or a condition called polycystic ovary syndrome (PCOS). PCOS is a common cause of infertility and can put women at risk of developing diabetes and other metabolic health problems. PCOS affects an estimated 7 percent to 10 percent of women of childbearing age, according to the Hormone Health Network. When pregnant women with PCOS or gestational diabetes take metformin, the medication crosses the placenta and is passed to the fetus. "Our findings indicate the offspring of women who took metformin for PCOS during pregnancy are more likely to meet the criteria for obesity or overweight than children whose mothers were given a placebo during pregnancy," said the study's first author, Liv Guro Engen Hanem, M.D., of the Norwegian University of Science and Technology in Trondheim, Norway. "The results were surprising, since limited past research in this area had suggested metformin would have a protective effect on the children's metabolic health." The researchers invited parents of 292 children who participated in two previous randomized clinical trials to be part of this study. In the previous trials, pregnant women with PCOS were assigned to take either metformin or a placebo during pr Continue reading >>
Metformin In Pregnancy May Increase Childhood Obesity Risk
Metformin in Pregnancy May Increase Childhood Obesity Risk Children born to women who take a commonly used diabetes medication during pregnancy may have an increased risk of being overweight or obese, according to new data from two Norwegian studies. Women with polycystic ovary syndrome (PCOS), gestational diabetes, type 2 diabetes, and even obesity are increasingly prescribed metformin during pregnancy, with studies indicating that the drug reduces the risk of PCOS-related complications. Although it metformin is known to crossthe placenta, the long-term impact of such intrauterine exposure on the offspring remains unclear, with previous investigations yielding conflicting results. Now a follow-up study of two randomized controlled trials suggests that, contrary to expectations, children exposed to metformin in utero may have a higher average weight at 4 years of age than children not exposed. The findings were published online February 27 in the Journal of Clinical Endocrinology & Metabolism. Moreover, the data from 182 children reveal that those whose mothers took metformin during pregnancy were more than twice as likely to be overweight or obese than those who took placebo, with the effect appearing to occur from age 6 months. "The results were surprising, since limited past research in this area had suggested metformin would have a protective effect on the children's metabolic health," said lead author Liv Guro Engen Hanem, PhD candidate, of the Norwegian University of Science and Technology in Trondheim, in a press release by the Endocrine Society. "Few studies have examined the long-term health of children born to women with PCOS who took metformin. Our findings indicate more research is needed to determine its effects on children who were exposed in the womb," s Continue reading >>
Global Metformin Hydrochloride Market Historical (2012-2018) And - News, Weather And Sports For Lincoln, Ne; Klkntv.com
Global Metformin Hydrochloride Market Historical (2012-2018) and - News, Weather and Sports for Lincoln, NE; KLKNTV.com Global Metformin Hydrochloride Market Historical (2012-2018) and Estimated Forecast (2018-2023) Covered in a Latest Research Metformin Hydrochloride Market report provides detailed analysis about production, revenue, gross margin, consumption value, consumption volume, sale price, import, export, and forecast to 2023 Pune, India April 9, 2018 /MarketersMedia/ Objective of Global Metformin Hydrochloride Market report is to provide detailed analysis of the market structure along with forecast of the various segments and sub-segments. This report will also provide insights about factors affecting the market growth. To analyze the Metformin Hydrochloride market based on various factors- price analysis, supply chain analysis, Porte five force analysis etc. This report also profile key players in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market. Get more insight about this report at: Metformin Hydrochloride Market report analyze the Metformin Hydrochloride industry from two aspects. One part is about its production and the other part is about its consumption. In terms of its production analysis about production, revenue, gross margin of its main manufacturers and the unit price that they offer in different regions from 2012 to 2018 is provided. In terms of its consumption this report covers consumption volume, consumption value, sale price, import and export in different regions from 2012 to 2018. Key companies profiled in this report are Bristol-Mayers Squibb, Shouguang Fukang Pharmaceutical, Harman Finochem, Vistin Pharma, Cr Double-Crane, Keyuan Pharmaceutical, Farmhispania Group, Shijiazhu Continue reading >>
Metformin In Pregnancy Linked To Child Obesity
Metformin in pregnancy linked to child obesity Metformin in pregnancy linked to child obesity Taking the common type 2 diabetes drug metformin during pregnancy has been linked to an increased risk of the child becoming overweight or obese. Metformin, a blood glucose-lowering drug, may be given to pregnant women who have gestational diabetes or polycystic ovary syndrome (PCOS). Treatment recommendations vary across different countries and in the UK, metformin is not routinely recommended for treating PCOS. It is thought around 10% of women suffer from PCOS which can cause infertility and is linked with increased risk of developing type 2 diabetes . In a Norwegian study, researchers identified that children exposed to metformin in utero had a higher average weight aged four compared to children not exposed. The findings indicate a link rather than causation, however. In the study, women with PCOS were randomised to daily metformin or placebo. The children of these women were then followed up, with complete health data available for 154 children. Birth weight seemed unaffected but then became more apparent as the babies reached the six-month stage. The children were monitored at the age of four, when those exposed to metformin were heavier on average and more likely to be overweight or obese . The researchers will also monitor the children in the future when they turn eight to see if the weight trend has continued. The study's first author, Dr Liv Guro Engen Hanem, from the Norwegian University of Science and Technology in Trondheim, said: "The results were surprising, since limited past research in this area had suggested metformin would have a protective effect on the children's metabolic health." Dr Hanem added: "Few studies have examined the long-term health of childr Continue reading >>
Global Metformin Hydrochloride Market Historical (2012-2018) And - Kxxv-tv News Channel 25 - Central Texas News And Weather For Waco, Temple, Killeen |
Global Metformin Hydrochloride Market Historical (2012-2018) and - KXXV-TV News Channel 25 - Central Texas News and Weather for Waco, Temple, Killeen | Global Metformin Hydrochloride Market Historical (2012-2018) and Estimated Forecast (2018-2023) Covered in a Latest Research Metformin Hydrochloride Market report provides detailed analysis about production, revenue, gross margin, consumption value, consumption volume, sale price, import, export, and forecast to 2023 Pune, India April 9, 2018 /MarketersMedia/ Objective of Global Metformin Hydrochloride Market report is to provide detailed analysis of the market structure along with forecast of the various segments and sub-segments. This report will also provide insights about factors affecting the market growth. To analyze the Metformin Hydrochloride market based on various factors- price analysis, supply chain analysis, Porte five force analysis etc. This report also profile key players in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market. Get more insight about this report at: Metformin Hydrochloride Market report analyze the Metformin Hydrochloride industry from two aspects. One part is about its production and the other part is about its consumption. In terms of its production analysis about production, revenue, gross margin of its main manufacturers and the unit price that they offer in different regions from 2012 to 2018 is provided. In terms of its consumption this report covers consumption volume, consumption value, sale price, import and export in different regions from 2012 to 2018. Key companies profiled in this report are Bristol-Mayers Squibb, Shouguang Fukang Pharmaceutical, Harman Finochem, Vistin Pharma, Cr Double-Crane, Keyuan Pharmaceutica Continue reading >>
Beyond Diabetes, Metformin May Prove To Be A ‘wonder Drug’
In the past 2 decades, metformin has become a mainstay of type 2 diabetes management and is now the recommended first-line drug for treating the disease in the United States and worldwide. Available in the United States since 1995, metformin is an attractive therapy for clinicians and patients alike. Studies have found the agent to be safe and effective, and at about $4 for a 1-month supply of the generic, that option is affordable at a time when many prescription drugs are being priced out of reach for some patients. “Metformin is the first drug of choice, by all standards,” Oluwaranti Akiyode, PharmD, RPh, BCPS, CDE, professor and clinical pharmacist at Howard University School of Pharmacy, told Endocrine Today. “It’s a rarity that all experts agree on something. It is time-tested, proven, has good efficacy, a good safety profile and it’s cheap. Metformin has been around long before it came to the United States. That’s why I find it amazing that we only have one drug in that class.” New research is suggesting that metformin may hold promise in treating or preventing a whole host of conditions in patients with and without type 2 diabetes. Studies show metformin may be cardioprotective in patients with diabetes and beneficial in the presence of stable congestive heart failure. The agent also may help to increase pregnancy rate in polycystic ovary syndrome, provide breast and prostate cancer benefits, and offer neuroprotection that may reduce dementia and stroke risk, Akiyode said. Nir Barzilai, MD, an endocrinologist and director of the Institute for Aging Research at the Albert Einstein College of Medicine, said he hopes to work with the FDA to conduct an NIH/American Federation for Aging Research metformin trial later this year — Targeting Aging with M Continue reading >>
No Link Found For Metformin Or Statins And Ovarian Cancer
No link found for metformin or statins and ovarian cancer (HealthDay)In women with type 2 diabetes, no evidence was found of an association between the use of metformin or statins and the incidence of ovarian cancer, according to a study published online Feb. 7 in BJOG: An International Journal of Obstetrics and Gynaecology. Elina Urpilainen, from the University of Oulu in Finland, and colleagues used national registers to identify 137,643 women (>40 years old) diagnosed with type 2 diabetes in Finland from 1996 through 2011. The researchers found that 303 women were diagnosed with ovarian cancer during the follow-up period. Metformin was not associated with the incidence of ovarian cancer (hazard ratio, 1.02) compared to other oral antidiabetic medications. There was also no association noted between ovarian cancer incidence and statins (hazard ratio, 0.99). "No evidence of an association between the use of metformin or statins and the incidence of ovarian cancer in patients with type 2 diabetes was found," the authors write. USPSTF recommends against ovarian cancer screening (HealthDay)The U.S. Preventive Services Task Force (USPSTF) recommends against screening for ovarian cancer in asymptomatic women. These findings form the basis of a final recommendation statement published in the Feb. ... A new drug to delay the spread of ovarian cancer, which was developed from UCL research, has been licensed for use in the UK. Metformin may reduce cancer mortality risk (HealthDay)Metformin may reduce the risk of dying from some cancers for postmenopausal women with type 2 diabetes, according to a study published in the April 15 issue of the International Journal of Cancer. Common diabetes drug may help treat ovarian cancer A new study suggests that the common diabetes medicati Continue reading >>
Is Diabetes Pill An Anti-ageing Wonder Drug, And Magic Bullet To Treat Cancer And Alzheimer’s?
One of the hottest new anti-ageing drugs has in fact been around for a long time. Discovered in 1922, metformin was introduced as a medicine in France in 1957 and has been widely used for the treatment of type 2 diabetes – and it still is – but research now suggests it may have a number of additional health benefits. What’s more, it’s very affordable. Metformin is derived from a plant, French lilac, also known as goat’s rue, that has been used since the Middle Ages for the treatment of diabetes. It is also a staple in traditional Chinese medicine, where it is known as quei fu di huang wan and is used for diabetes as well as to treat elevated blood sugars and for preventive health. At one time the plant was fed to goats, as it was thought to improve milk production, thus the name goat’s rue. There are more than 700,000 people with diabetes in Hong Kong and that number is expected to jump to 1.02 million by 2030, according to Dr Rose Ting Zhao-wei, a specialist in endocrinology. Metformin is among the most common treatments for type 2 diabetes, but increasingly it is also being recognised as being able to do much more. A 2014 study at Cardiff University of more than 180,000 people found that when patients with diabetes were given metformin they lived longer than those without the condition. “That was the big leap to, ‘Wow, we should take it, why are diabetics healthier than we are’,” says Dr Lauren Bramley at Dr Bramley & Partners, a medical practice in Hong Kong’s Centrat district that focuses on wellness. We tend to lose insulin sensitivity as we age. Metformin’s use as an anti-ageing treatment revolves around the fact that it helps to increase sensitivity to insulin, which in turn lowers blood-sugar levels. Ageing is also associated with glycati Continue reading >>
Metformin Linked To Dementia, Parkinson's In Patients With T2dm
Metformin Use Linked to Increased Dementia, Parkinson's Risk in Patients With Diabetes VIENNA, Austria — Long-term use of the diabetes medication metformin may increase the risk for neurodegenerative disease in patients with type 2 diabetes mellitus (T2DM), new research suggests. In a cohort study that followed about 9300 patients with T2DM in Taiwan for up to 12 years, the risk for Parkinson's disease (PD) or Alzheimer's dementia was more than double during a 12-year period for those who took metformin vs those who did not — even after adjusting for multiple confounders. In addition, outcome risks increased progressively with higher dosage and longer duration of treatment. The results were presented here at AD/PD 2017: The 13th International Conference on Alzheimer's and Parkinson's Diseases by Yi-Chun Kuan, MD, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan. Interestingly, recent research has suggested that use of metformin may protect against neurodegenerative diseases. When asked about that, Dr Kuan told Medscape Medical News that "some studies have actually found positive [outcomes] but some have been negative ." So the researchers wanted to look into this using their own data. "We'd heard about a possible protective effect from metformin. However, we found the reverse," she said, but stressed that large-scale, prospective studies in other countries are needed to clarify the results. The investigators note that past research has shown a link between T2DM and increased risk for neurodegenerative diseases, but there's been "some question" about the association with specific diabetes medications. They examined records for patients with T2DM from the National Health Insurance research database of Taiwan, including 4651 who had metformin pre Continue reading >>
Is Metformin Really The World's First Anti-aging Wonder Drug?
Metformin is no new kid on the block. The so-called wonder drug has been healing people since the middle ages by way of French lilac (plant name:Galega officinalis), the active ingredient in todays metformin. The flower treated what we now know to be symptoms of diabetes. In 1922, the specific compound we now use today was first discovered. By 1950,French scientist Jean Sterne recognized the pills blood sugar-lowering abilities and began administering it to patients. Hes the guy that coined the term you might be more familiar with, Glucophage. AKA glucose eater. [insert diabetes Pacman] Today, metformin is the front-line medication for prediabetes and type 2 diabetes treatment. Study after study (after multiple other studies) has shown how the drug, coupled with lifestyle changes (like food choices, exercise, stress-levels) can delay or prevent diabetes altogether. Its also the go-to treatment for polycystic ovary syndrome (PCOS). Additionally, more and more talk continues to arise surrounding its benefits in type 1 diabetes. Metformin has resulted in decreased insulin dosing and decreased A1c in people with type 1 diabetes. (Ill be the first to admit: as a T1D, I lovemy metformin.) And as if thats not enough, countless other forms of research point to metformins beneficial qualities to cognitive function, as well as its anti-cancer, anti-cardiovascular disease, and anti-aging properties. Its that last property, anti-aging, that has scientists truly wondering, and studying, if metformin is the miracle drug. The worlds first anti-aging pill. It could be. And right now, scientists are studying exactly that in clinical trial TAME . While theres no true biological marker for aging, per se, scientists are, instead, measuring whether or not the pill can delay the onset of ch Continue reading >>
Diabetes Drug Use During Pregnancy Linked To Child's Weight
Follow all of ScienceDaily's latest research news and top science headlines ! Diabetes drug use during pregnancy linked to child's weight Children born to moms who took metformin face increased risk of obesity When women take the common diabetes medication metformin during pregnancy, it may put their children at increased risk of having obesity or overweight. When women take the common diabetes medication metformin during pregnancy, it may put their children at increased risk of having obesity or overweight. A growing number of pregnant women are taking metformin to treat gestational diabetes or a condition called polycystic ovary syndrome (PCOS). PCOS is a common cause of infertility and can put women at risk of developing diabetes and other metabolic health problems. PCOS affects an estimated 7 percent to 10 percent of women of childbearing age, according to the Hormone Health Network. When pregnant women with PCOS or gestational diabetes take metformin, the medication crosses the placenta and is passed to the fetus. "Our findings indicate the offspring of women who took metformin for PCOS during pregnancy are more likely to meet the criteria for obesity or overweight than children whose mothers were given a placebo during pregnancy," said the study's first author, Liv Guro Engen Hanem, M.D., of the Norwegian University of Science and Technology in Trondheim, Norway. "The results were surprising, since limited past research in this area had suggested metformin would have a protective effect on the children's metabolic health." The researchers invited parents of 292 children who participated in two previous randomized clinical trials to be part of this study. In the previous trials, pregnant women with PCOS were assigned to take either metformin or a placebo during pr Continue reading >>
How I Learned To Stop Worrying And Love Metformin
How long should we allow metformin to remain the bogeyman in CKD? Should MALA scare us from ever letting our patients benefit from metformin? Join us as we discuss some rare prospective data on metformin in moderate to severe CKD. **Disclaimer- this study discusses off label use of metformin in later stage CKD. The discussion below is based upon the above paper and does not constitute a change in the product labeling. the current recommended use of metformin based upon kidney function is below. Metformin is a mainstay of treatment in pre-diabetes and diabetes.However, it lives with the sins of its predecessor, phenformin. Phenformin was discovered in the 50's and became a popular in the 60's. By the 70's it began to lose ground as knowledge of it tendency to cause lactic acidosis became wide spread. Phenformin was banned from the US in 1977 . It is still available in a handful of countries (Italy, Brazil, Uruguay, China, Poland, Greece and Portugal)and it sometimes slips into adulterated herbal medicines .Phenformin was estimated to cause 64 cases of lactic acdiosis per 100,000 patient-years. Metformin, the second biguanide, always lived with questions about its safety in patients with Chronic Kidney Disease (CKD). When first approved in 1994, the FDA restricted it from patients with CKD, due to lactic acidosis concern since metformin is largely excreted by the kidneys. Metformin associated lactic acidosis (MALA) is a feared and deadly condition. The FDA revised its warning on metformin and CKD in April 2016. Metformin remained contraindicated in patients with eGFR <30 ml/min/1.73m2.They advised that metformin not be started in patients with eGFR 30-45 ml/min/1.73m2, however if a patient was already on the drug and their eGFR decreased to this level, then the risks and Continue reading >>
What Comes After Metformin In Type 2 Diabetes?
What Comes After Metformin in Type 2 Diabetes? Does Choice of Second-line Therapy Affect Glycemic Control? Until 2012, the American Diabetes Association (ADA) recommended lifestyle and metformin as first-line therapy for glycemic management in type 2 diabetes, followed by a sulfonylurea (SU) or insulin for additional A1c reduction.[ 1 ] The rationale was that SUs were well validated as a glucose-lowering therapy, even though the risk for hypoglycemia was recognized, along with concerns about increased cardiovascular risk,[ 2 ] especially in combination with metformin.[ 3 ] Today, with many more second-line options available, the ADA's new guidelines[ 4 ] open the door to whichever therapy is best for the individual patient. But what exactly does that mean? Khunti and colleagues[ 5 ] analyzed data from 10,256 patients who initiated a second-line glucose-lowering therapy after treatment with metformin monotherapy between 2011 and 2014 in Germany and the United Kingdom. The main outcome of interest was change in A1c at 6 months. The researchers assessed the impact of various factors, including demographics, baseline A1c, time since diabetes diagnosis, and different types of second-line therapy, including SU or dipeptidyl peptidase-4 (DPP-4) inhibitor alone, SU or DPP-4 inhibitor with metformin, and insulin with or without other agents. Most patients added a therapy to metformin, the most common of which was SU (41%) followed by DPP-4 inhibitor (31%). Baseline A1c was 8.7% overall and 9.2% and 8.4% for SU and DPP-4 inhibitor combined with metformin, respectively. Patients initiating insulin experienced the largest absolute 6-month change in A1c (-2.1%), followed by those adding SU to metformin (-1.7%). However, after adjusting for baseline A1c, all therapies provided a dro Continue reading >>
Indian Drugmakers Combine 2 Diabetes Drugs In 1 Pill, Raising Concern : Goats And Soda : Npr
Metformin pills they're a go-to drug for type 2 diabetics move through a sorting machine at a pharmaceutical plant in India. Sara Hylton/Bloomberg via Getty Images hide caption Metformin pills they're a go-to drug for type 2 diabetics move through a sorting machine at a pharmaceutical plant in India. "India is the diabetes capital of the world!" How Diabetes Got To Be The No. 1 Killer In Mexico That was a headline two years ago in the Times of India. And that's not a case of media hype. India has a huge diabetes problem: nearly 70 million people are grappling with the disease. India also has a prolific pharmaceutical industry pumping out hundreds of innovative drugs to treat diabetes and other ailments. But researchers say it's unclear how well some of these medicines work, or even if they're safe, because the drugs haven't gone through adequate clinical trials. "We're really puzzled as to why many of these medicines are available," says Allyson Pollock , the director of the Institute of Health and Society at Newcastle University in England, "because some of these weren't even approved by the medicines regulator in India." Pollock and her colleagues have just come out with an analysis of regulatory approval procedures for diabetes drugs in the Indian state of Maharashtra. The findings reinforce her skepticism. One example involves the drug metformin, a workhorse of diabetes treatment. According to the Mayo Clinic metformin is usually the first medicine prescribed to people with type 2 diabetes, helping control high blood sugar. In the U.S. most metformin comes in pills in which metformin is the only active ingredient. But not in India. "To our absolute amazement we found that metformin was not the most frequently available medicine," she says. "Instead we found huge nu Continue reading >>
Metformin Lowers Risk Of Late Miscarriage, Preterm Birth In Pregnant Women With Pcos
Metformin lowers risk of late miscarriage, preterm birth in pregnant women with PCOS Metformin lowers risk of late miscarriage, preterm birth in pregnant women with PCOS Associate Director, Communications and Media Relations Chicago, IL - The oral diabetes medication metformin seems to reduce the chance of a late miscarriage and premature birth among women with polycystic ovary syndrome (PCOS) but does not affect their rate of developing gestational diabetes, a multicenter study finds. The results were presented Tuesday at ENDO 2018, the Endocrine Societys 100th annual meeting in Chicago, Ill. Women with PCOS are at increased risk for infertility, and if they do become pregnant, they have a higher chance of pregnancy complications, including miscarriage and preterm birth, as well as a form of diabetes during pregnancy called gestational diabetes. PCOS is the most common hormone disorder among females of childbearing age, affecting up to 10 percent of these women, according to the Hormone Health Network. A total of 487 pregnant women with PCOS participated in the study at 14 research centers in Norway, Sweden and Iceland. They were randomly assigned to receive either daily metformin (2,000 milligrams) or an inactive placebo from their first trimester to delivery, but did not know which drug they received. The average age of participants was 29 years old. After excluding women who dropped out of the study, the researchers found that a combined incidence of late miscarriage (pregnancy loss in the second trimester) and premature birth (at less than 37 weeks of pregnancy) was almost halved in the women receiving metformin versus placebo. Only 9 (5 percent) of the 211 women who completed the study in the metformin group experienced late miscarriage or preterm birth, compared Continue reading >>
